In a milestone Alzheimer’s disease study for lecanemab, Worldwide encountered aggressive timeline expectations, multiple protocol amendments, and an unusual adverse event profile. Due to Worldwide’s adaptable, flexible approach, our teams still managed to deliver the study on time and on budget. See how our partnership with the sponsor led to study success.
Operational & Strategic Excellence in Delivery of a Global Phase III Trial
Outcome: FDA Approval
Read more